Clinical features and management of intoxication due to hallucinogenic drugs.
J B Leikin, A J Krantz, M Zell-Kanter, R L Barkin, D O Hryhorczuk
Medical toxicology and adverse drug experience 1989 DOI: 10.1007/bf03259916 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | The review states that hallucinogens produce their effects at non-toxic doses and that each drug's characteristic behavioral effects relate to serotonergic, dopaminergic, or adrenergic activity. It reports that cocaine produces simple hallucinations, PCP complex hallucinations resembling paranoid psychosis, and LSD a combination of hallucinations, pseudohallucinations, and illusions, and that management should target the specific drug and symptom complex. |
Abstract
Hallucinogenic drugs are unique in that they produce the desired hallucinogenic effects at what are considered non-toxic doses. The hallucinogenic drugs can be categorised into 4 basic groups: indole alkaloid derivatives, piperidine derivatives, phenylethylamines and the cannabinols. The drugs reviewed include lysergic acid diethylamide (LSD), phencyclidine (PCP), cocaine, amphetamines, opiates, marijuana, psilocybin, mescaline, and 'designer drugs.' Particularly noteworthy is that each hallucinogen produces characteristic behavioural effects which are related to its serotonergic, dopaminergic or adrenergic activity. Cocaine produces simple hallucinations, PCP can produce complex hallucinations analogous to a paranoid psychosis, while LSD produces a combination of hallucinations, pseudohallucinations and illusions. Dose relationships with changes in the quality of the hallucinatory experience have been described with amphetamines and, to some extent, LSD. Flashbacks have been described with LSD and alcohol. Management of the intoxicated patient is dependent on the specific behavioural manifestation elicited by the drug. The principles involve differentiating the patient's symptoms from organic (medical or toxicological) and psychiatric aetiologies and identifying the symptom complex associated with the particular drug. Panic reactions may require treatment with a benzodiazepine or haloperidol. Patients with LSD psychosis may require an antipsychotic. Patients exhibiting prolonged drug-induced psychosis may require a variety of treatments including ECT, lithium and l-5-hydroxytryptophan.
Citations in the library
Cited by 10
- Bufo toads and bufotenine: fact and fiction surrounding an alleged psychedelic. Journal of Psychoactive Drugs 1996
- Chemistry and Toxicology of Major Bioactive Substances in Inocybe Mushrooms International Journal of Molecular Sciences February 23, 2021
- Occurrence and use of hallucinogenic mushrooms containing psilocybin alkaloids TemaNord May 19, 2009
- Analysis of the psychoactive terpenoid salvinorin A content in five Salvia divinorum herbal products. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy September 1, 2006
- Effects of mescaline and some of its analogs on cholinergic neuromuscular transmission Neuropharmacology February 1, 1993
and 5 more in the library
Cites 37
- Medical Toxicology: Diagnosis and Treatment of Human Poisoning. Annals of Internal Medicine March 1, 1988
- Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens Journal of Psychoactive Drugs October 1, 1986
- Subjective Reports of the Effects of MDMA in a Clinical Setting Journal of Psychoactive Drugs October 1, 1986
- ADVERSE REACTIONS TO PSYCHEDELIC DRUGS. A REVIEW OF THE LITERATURE The Journal of Nervous and Mental Disease October 1, 1984
- 'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA JAMA March 27, 1987
and 32 more in the library